Verve Therapeutics (NASDAQ:VERV) Upgraded to "Hold" at Wall Street Zen

Verve Therapeutics (NASDAQ:VERV - Get Free Report) was upgraded by analysts at Wall Street Zen to a "hold" rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also recently weighed in on the company. Jefferies Financial Group cut Verve Therapeutics from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $28.00 to $11.00 in a research report on Wednesday, June 18th. Lifesci Capital downgraded Verve Therapeutics from a "strong-buy" rating to a "hold" rating and set a $12.00 price target for the company. in a report on Wednesday, June 18th. Cantor Fitzgerald upgraded Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. William Blair downgraded shares of Verve Therapeutics from a "strong-buy" rating to a "market perform" rating in a report on Tuesday, June 17th. Finally, Canaccord Genuity Group cut shares of Verve Therapeutics from a "strong-buy" rating to a "hold" rating and lowered their target price for the stock from $39.00 to $13.00 in a research note on Tuesday, June 17th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $14.57.

Verve Therapeutics Stock Up 0.9%

Shares of Verve Therapeutics stock opened at $11.21 on Friday. The firm's 50 day moving average price is $8.62 and its 200-day moving average price is $6.82. Verve Therapeutics has a 52-week low of $2.86 and a 52-week high of $11.40. The company has a market cap of $998.81 million, a P/E ratio of -5.31 and a beta of 2.23.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. The company had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. As a group, equities research analysts forecast that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VERV. Farther Finance Advisors LLC increased its holdings in Verve Therapeutics by 8,746.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 2,477 shares of the company's stock worth $28,000 after buying an additional 2,449 shares during the period. KFG Wealth Management LLC purchased a new stake in shares of Verve Therapeutics in the 1st quarter valued at $46,000. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Verve Therapeutics in the first quarter worth $47,000. E Fund Management Co. Ltd. acquired a new stake in shares of Verve Therapeutics in the first quarter worth $48,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Verve Therapeutics in the fourth quarter worth $50,000. 97.11% of the stock is currently owned by hedge funds and other institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.